Healthline reports that as five second-generation antipsychotics (SGAs) lose patent protection, Medicaid expenditures for antipsychotics are projected to be cut in half over the next five years. But some worry that the decrease in spending may lead policymakers to lift existing restrictions on antipsychotics at a time when most SGAs are prescribed to children for off-label reasons.
MIA relies on the support of its readers to exist. Please consider a donation to help us provide news, essays, podcasts and continuing education courses that explore alternatives to the current paradigm of psychiatric care. Your tax-deductible donation will help build a community devoted to creating such change.